Laurent Guilleminault1,2,3, Michael Mounié4,5, Agnès Sommet6, Claire Camus3, Alain Didier7,2,3, Laurent L Reber2, Nadège Costa4,5, Cécile Conte6. 1. Pôle des Voies Respiratoires, Service de Pneumo-allergologie, Centre Hospitalo-Universitaire de Toulouse, 24 chemin de Pouvourville, 31059 Toulouse, France. 2. Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, CNRS U5282, University of Toulouse, Toulouse, France. 3. CRISALIS F-CRIN, Toulouse, France. 4. Unité d'Evaluation Médico-Economique, Centre Hospitalier Universitaire, Toulouse, France. 5. INSERM-UMR 1295-Center for Epidemiology and Research in POPulation health (CERPOP), Inserm, UPS, Université de Toulouse, Toulouse, France. 6. Unité Méthodologie, Data Management, Analyses Statistiques, Centre d'Investigation Clinique 1436, Service de pharmacologie médicale, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France. 7. Pôle des Voies Respiratoires, Service de Pneumo-allergologie, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
Abstract
BACKGROUND: Although asthma mortality declined sharply until the mid-2000s, a stagnation in mortality has been observed over the past decade in different countries. OBJECTIVE: The objective of this study is to describe healthcare resource consumption for patients who died from asthma in France. METHOD: This study was conducted using data from the French National Health Data System. Patients who died from asthma between 2013 and 2017 were identified by the ICD10 codes J45 and J46. Health care consumption data were collected. Patients were categorized into four categories according to age: ⩾75, (18-75), (12-18), (0-12). Daily doses of ICS were categorized according to GINA guidelines. RESULTS: A total of 3829 patients were included. No ICS or an inadequate ICS dose was observed in 43.8%, 50.6%, 48.1%, and 54.0% of patients aged ⩾75, (18-74), (12-18), and (0-12) years, respectively. Dispensation of six or more SABA canisters was observed in 37.2%, 49.0%, and 70.3% of patients aged of ⩾75, (18-75), and (12-18) years, respectively. Omalizumab dispensation rate was very low [1.1% and 2.8% in patients aged ⩾75 and (18-75) years)]. The proportion of patients with a pulmonologist office visit was 13.8% and 14.6% in patients ⩾75 and (18-75) years, respectively. A lung function test was noted in only 18.6%, 28.3%, and 25.9% of patients ⩾75, (18-75) and (12-18) years, respectively. CONCLUSION: Half of the patients who died from asthma received inadequate ICS doses and only a small proportion had access to biological therapies. Less than 15% were referred to a specialist.
BACKGROUND: Although asthma mortality declined sharply until the mid-2000s, a stagnation in mortality has been observed over the past decade in different countries. OBJECTIVE: The objective of this study is to describe healthcare resource consumption for patients who died from asthma in France. METHOD: This study was conducted using data from the French National Health Data System. Patients who died from asthma between 2013 and 2017 were identified by the ICD10 codes J45 and J46. Health care consumption data were collected. Patients were categorized into four categories according to age: ⩾75, (18-75), (12-18), (0-12). Daily doses of ICS were categorized according to GINA guidelines. RESULTS: A total of 3829 patients were included. No ICS or an inadequate ICS dose was observed in 43.8%, 50.6%, 48.1%, and 54.0% of patients aged ⩾75, (18-74), (12-18), and (0-12) years, respectively. Dispensation of six or more SABA canisters was observed in 37.2%, 49.0%, and 70.3% of patients aged of ⩾75, (18-75), and (12-18) years, respectively. Omalizumab dispensation rate was very low [1.1% and 2.8% in patients aged ⩾75 and (18-75) years)]. The proportion of patients with a pulmonologist office visit was 13.8% and 14.6% in patients ⩾75 and (18-75) years, respectively. A lung function test was noted in only 18.6%, 28.3%, and 25.9% of patients ⩾75, (18-75) and (12-18) years, respectively. CONCLUSION: Half of the patients who died from asthma received inadequate ICS doses and only a small proportion had access to biological therapies. Less than 15% were referred to a specialist.
Authors: Aurélie Bannay; Christophe Chaignot; Pierre-Olivier Blotière; Mickaël Basson; Alain Weill; Philippe Ricordeau; François Alla Journal: Med Care Date: 2016-02 Impact factor: 2.983
Authors: Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Frank C Albers; Hana Müllerová; Necdet B Gunsoy; Ji-Yeon Shin; Linda M Nelsen; Eric S Bradford; Sarah M Cockle; Robert Y Suruki Journal: J Asthma Date: 2017-06-16 Impact factor: 2.515